FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC
The FDA granted breakthrough therapy designation to durvalumab for patients with locally advanced, unresectable NSCLC who do not relapse after platinum-based chemoradiation.
The FDA granted breakthrough therapy designation to durvalumab for patients with locally advanced, unresectable NSCLC who do not relapse after platinum-based chemoradiation.
Women with metastatic, HER2-positive breast cancer with tumors that express high levels of HER2 derived the greatest survival benefit from treatment with trastuzumab emtansine (T-DM1), according to research presented at AACR 2013.
Using autologous T-cell immunotherapy to attack leukemia cells showed early promise in two children diagnosed with relapsing acute lymphoblastic leukemia after bone marrow transplant, according to research presented at AACR 2013.
Melanoma survivors often do not take protective measures to prevent skin cancer recurrence, according to research presented at AACR 2013.
The number of benign findings for suspected lung cancers varies by state, suggesting a national lung cancer screening program would vary geographically, according to research presented at AACR 2013.
The RNA interference (RNAi) drug TKM-080301 can be safely administered to patients with advanced solid tumors or lymphoma, and some patients show therapeutic benefit, according to research presented at AACR 2013.
Increased exposure to traffic-related air pollution during pregnancy and early life was associated with a higher incidence of acute lymphoblastic leukemia, retinoblastoma, and germ cell tumors, according to research presented at AACR 2013.
Newly identified biomarkers may predict sensitivity to combined MEK and PI3K inhibition in patients with KRAS-mutant NSCLC, according to research presented at AACR 2013.
The novel oral selective AKT pathway inhibitor ARQ 092 exhibits a manageable safety profile among patients with advanced solid tumors, according to research presented at AACR 2013.